This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction

Tuesday, July 29, 2014

Submitted by


Source Name: Journal of Clinical Oncology


Andrew R. Davies, James A. Gossage, Janine Zylstra, Fredrik Mattsson, Jesper Lagergren, Nick Maisey, Elizabeth C. Smyth, David Cunningham, William H. Allum and Robert C. Mason

Using data from 2 centers in London, outcomes after induction therapy and resection for esophageal cancer were analyzed according to the pathological response to induction therapy.  Downstaging was the strongest predictor of survival (HR 0.43).  Downstaging was also associated with a lower rate of local recurrence (6% vs 13%) and systemic recurrence (19% vs 29%).  Pathologic stage after induction therapy was a stronger predictor of survival that was pretreatment clinical stage.

Add comment

Log in or register to post comments